Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of NTQ5082 in paroxysmal nocturnal hemoglobinuria
CTR20244637Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NTQ5082 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2025; status: active.
02
Drugs
NTQ5082
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20244637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244637.